EFS and OS from first line-treatment, stratified according to the TP53 mutation load. (A) EFS of the whole cohort. (B) EFS in patients with unmutated IGHV. (C) OS of the whole cohort. (D) OS in patients stratified according to a targeted treatment. Dashed line, patients received targeted treatment with either BcR inhibitors (ibrutinib, idelalisib, or acalabrutinib) or bcl2 inhibitor (venetoclax) in later stages of the disease. Patients undergoing allogeneic hemapoietic stem cell transplant were excluded (n = 14). (E) OS in a cohort with unmutated IGHV, with patients switched to targeted agents or undergoing allogeneic hemapoietic stem cell transplant excluded. All analyses were also performed for time to second treatment and for FCR-treated patients only, and very similar results were obtained (data not shown).